|
Group
|
LDL-C
|
HDL-C
|
VLDL-C
|
|---|
|
NC
|
35.5 ± 1.12*
|
27.5 ± 0.99
|
12 ± 0.67
|
|
HLC
|
280.12 ± 4.36*
|
22.28 ± 0.56
|
48.26 ± 1.45
|
|
(+646.66%)a
|
(−20%)a
|
(+300.04%)a
|
|
FVT-1
|
81.15 ± 2.19*
|
26.63 ± 0.74
|
19.09 ± 0.81
|
|
(−71.07%)a
|
(+19.3%)a
|
(−60.41%)a
|
|
FVT-2
|
39.5 ± 1.37*
|
29.7 ± 1.15
|
13.08 ± 0.64
|
|
(−85.89%)a
|
(+35%)a
|
(−71.40%)a
|
|
CT
|
43.26 ± 1.25*
|
28.2 ± 1.14
|
12.54 ± 0.63
|
|
(−84.55%)a
|
(+28.18%)a
|
(−74.01%)a
|
|
AT
|
37.88 ± 1.18*
|
28.4 ± 1.15
|
11.72 ± 0.52
|
|
(−86.47%)a
|
(+29.09%)a
|
(−75.71%)a
|
- *Values are mean (mg/dl) ± SD from LDL-C, HDL-C and VLDL-C, isolated from plasma of 5 rats in each group.
- NC, normal control; HLC, triton induced hyperlipidemic control; FVT-1, fed 50 mg FVBM extract/rat; FVT-2, fed 100 mg FVBM extract/rat; CT, fed 1 mg F18 bioactive compound/rat and AT, given 1 mg atorvastatin/rat once.
- Significantly different from NC at ap < 0.001.
- Significantly different from HLC at ap < 0.001.
